Core Viewpoint - Company Kubo Medical-B (02216) plans to acquire 157,800 shares of Series B preferred stock of Valgen Holding Corporation for $15 million, representing 1.05% of the target company's fully diluted shares as of the announcement date [1] Group 1: Acquisition Details - The acquisition is being made through Broncus China Holding Corporation, a wholly-owned subsidiary of Kubo Medical-B [1] - Valgen Holding Corporation specializes in providing systemic solutions for diseases such as mitral regurgitation and tricuspid regurgitation [1] - The products of Valgen include the DragonFly™ mitral valve repair device and the DragonFly-TTM tricuspid valve repair device [1] Group 2: Strategic Rationale - The board believes that the acquisition presents a valuable opportunity to establish a comprehensive diagnostic and treatment platform for cardiopulmonary diseases, given the similarities and connections between structural heart diseases and pulmonary diseases [1] - The collaboration is expected to leverage the company's expertise in chronic obstructive pulmonary disease (COPD) to strengthen the foundation for a comprehensive cardiopulmonary diagnostic and treatment platform [1] - The acquisition also provides an opportunity to enhance the company's R&D capabilities by applying structural heart disease treatment technologies to pulmonary disease treatments and vice versa [1]
堃博医疗-B(02216)拟1500万美元收购Valgen Holding Corporation15.78万股B系列优先股